Molly M. Lee

2012-2017 Medicinal Chemistry University of Kansas, Lawrence, KS, United States 
 2017-2020 National Cancer Institute, Rockville, MD, United States 
 2020- FDA, CDER 
"Molly Lee"
Mean distance: (not calculated yet)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Lee YH, Lee MM, De Silva DM, et al. (2021) Autocrine signaling by receptor tyrosine kinases in urothelial carcinoma of the bladder. Plos One. 16: e0241766
Apolo AB, Nadal R, Tomita Y, et al. (2020) Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. The Lancet. Oncology
Knewtson KE, Perera C, Hymel D, et al. (2019) Antibody-Drug Conjugate that Exhibits Synergistic Cytotoxicity with an Endosome-Disruptive Peptide. Acs Omega. 4: 12955-12968
Punchi Hewage A, Yao H, Nammalwar B, et al. (2019) Small molecule inhibitors of the BfrB-Bfd interaction decrease Pseudomonas aeruginosa fitness and potentiate fluoroquinolone activity. Journal of the American Chemical Society
Lee MM, Gao Z, Peterson BR. (2017) Synthesis of a Fluorescent Analogue of Paclitaxel that Selectively Binds Microtubules and Sensitively Detects Efflux by P-Glycoprotein. Angewandte Chemie (International Ed. in English)
Lee MM, Peterson BR. (2016) Quantification of Small Molecule-Protein Interactions using FRET between Tryptophan and the Pacific Blue Fluorophore. Acs Omega. 1: 1266-1276
See more...